跳至主要内容
临床试验/NCT01763255
NCT01763255已完成1 期

The Safety of Multiple Intrathecal Injection of Bone Marrow Derived CD133 Cells in Patients With Cerebral Palsy

Royan Institute2 个研究点 分布在 2 个国家目标入组 8 人开始时间: 2012年4月最近更新:
适应症
干预措施

试验速览

阶段
1 期
状态
已完成
入组人数
8
试验地点
2
主要终点
sensory dysfunction

研究概览

简要总结

Cerebral palsy (CP) is condition, sometimes thought of as a group of disorders that can involve brain and nervous system functions such as movement, learning, hearing, seeing, and thinking.Cerebral palsy is caused by injuries or abnormalities of the brain. Most of these problems occur as the baby grows in the womb, but they can happen at any time during the first 2 years of life, while the baby's brain is still developing.Bone marrow derived stem cells are known as a effective therapy.

In this study the investigators evaluate the side effect of multiple intrathecal injection of bone marrow stem cell in patients with cerebral palsy.

详细描述

In this study,we evaluate the safety of multiple transplantation of bone marrow derived stem cells.the children(4-12years)with definite diagnose of cerebral palsy enroll to the study.first of all all the physical exam,laboratory test,EEG and MRI is done.after hospital admission,the patient underwent bone marrow transplantation.In laboratory,the cells are separated and prepared for injection.after 24hours the neurosurgeon inject the cells(intrathecal).the patient would be under observed for 48hours.If no allergic reaction or abnormal neurological symptoms accrued,patients can be discharged and would be followed up 1,3 and 6months after injection.at the end of the 6months,the patients would receive second injection as same as the previous process.then they are followed at 1,3 immediate local and systemic side effect(fever,respiratory distress,erythema,rash,increase of heart rate or blood pressure)and neurological symptoms:motor dysfunction,sensory dysfunction,sphincter dysfunction,nausea,vomiting,head ache.EEG,MRI,GMFM66

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
4 Years 至 12 Years(Child)
性别
All
接受健康志愿者

入选标准

  • diagnosis of spastic quadriplegic CP Children must be between the ages of 4 and 12 years Children must be cleared by an orthopedic surgeon for risk of hip subluxation or dislocation and cannot have significant scoliosis (curvature > 40 degrees) Children must be seizure-free or seizure controlled

排除标准

  • Children who have a diagnosis of "mixed" types of CP (i.e. athetosis) or other movement disorders (i.e. ataxia) Children who have had a selective dorsal rhizotomy, are presently are receiving intrathecal Baclofen, or have changed their spasticity medications in the past 6 months.
  • Children who have a metallic or electrical implants

研究组 & 干预措施

CD133 transplantation

Experimental

The patients with cerebral palsy that underwent CD133 transplantation.

干预措施: stem cell intrathecal injection (Biological)

Control

No Intervention

The patients with cerebral palsy that underwent regular observation.

结局指标

主要结局

sensory dysfunction

时间窗: 6months

Evaluation the sensory dysfunction after intrathecal injection of CD133 cells.

motor dysfunction

时间窗: 6months

Evaluation the motor dysfunction 6months after intrathecal injection.

unconsciousness

时间窗: 48hours

Evaluation the rate of unconsciousness during 48hours after cell transplantation.

fever

时间窗: 48hours

Evaluation the symptom of infection like fever 48hours after cell transplantation.

次要结局

  • motor improvement(6months)
  • Balance improvement(6months)
  • Spasm(6months)

研究者

申办方类型
Other Gov
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

Multiple Transplantation of Bone Marrow Derived... | 临床试验